Cancer Cell International, published by BMC, is a transformative open-access journal established in 2001, dedicated to advancing the field of oncology and cancer research. With its ISSN number not specified and an E-ISSN of 1475-2867, the journal proudly operates from the United Kingdom, located at CAMPUS, 4 Crinan St, London N1 9XW, England. Renowned for its rigorous peer-review process, Cancer Cell International has made significant strides, securing a Q2 ranking in Cancer Research and Q1 rankings in both Genetics and Oncology as of 2023. It ranks impressively in Scopus, featuring in the top quintile of Genetics (#37/347) and Oncology (#52/404), indicating its importance within the scientific community. The journal's broad scope caters to a diverse array of topics within cancer biology, making it an invaluable resource for researchers, professionals, and students seeking to stay at the forefront of cancer science. With a commitment to disseminating high-quality research, Cancer Cell International invites scholars to explore innovative findings and contribute to the collective effort of combating cancer.

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

NATURE REVIEWS CANCER, a premier journal published by NATURE PORTFOLIO, stands as a cornerstone in the field of oncology, focusing on delivering high-quality, comprehensive reviews that shape our understanding of cancer biology, prevention, and treatment. With an impressive impact in the academic community, it ranks Q1 in both Cancer Research and Oncology categories as of 2023, further denoted by a remarkable Scopus ranking as the top journal in Cancer Research and second in Oncology. This ensures that published articles not only set the standard for scientific excellence but also drive significant advancements in cancer research methodologies and practices. The journal's targeted audience, including researchers, practitioners, and students, will greatly benefit from its insightful analyses and interdisciplinary approach. While it operates under a traditional subscription model, the rich content and vast expertise presented in its articles foster a global dialogue on cancer-related issues, making it an essential resource for anyone dedicated to the advancement of cancer science.

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

Veterinary and Comparative Oncology is a leading academic journal published by WILEY, providing a vital platform for the dissemination of groundbreaking research in the field of veterinary oncology. With an impressive impact factor and ranked as Q1 in the Veterinary (Miscellaneous) category for 2023, the journal is recognized for its quality and influence, placing it in the top 10% of its field. Covering a wide array of topics, from the pathogenesis of tumors in animals to innovative treatment strategies, it aims to enhance the understanding of cancer biology and therapy in veterinary medicine. The journal has an E-ISSN of 1476-5829, with its scope expanding from 2007 to 2024, reflecting an ongoing commitment to the advancement of veterinary science. Located in the United Kingdom, its global reach facilitates the exchange of knowledge among researchers, professionals, and students. For those interested in significant and impactful studies, Veterinary and Comparative Oncology remains an essential resource in the ever-evolving landscape of veterinary medicine.

Cell Death & Disease, published by SpringerNature, is a premier open-access journal dedicated to disseminating high-quality research on the mechanisms and implications of cell death, disease pathology, and therapeutic responses. Since its inception in 2010, the journal has quickly established itself within the top tier of academic publishing, achieving a notable impact factor and earning Q1 rankings in several critical categories including Cancer Research, Cell Biology, Cellular and Molecular Neuroscience, Immunology, and Medicine (miscellaneous). With its commitment to open access, Cell Death & Disease ensures that groundbreaking research is available to a global audience, fostering collaboration and advancing knowledge across disciplines. Residing at the forefront of crucial scientific discourse, this journal not only attracts submissions from leading researchers but also significantly influences the fields of molecular biology, immunology, and neurology. By bridging the gap between basic science and clinical applications, it provides vital insights for professionals, academicians, and students alike.

MOLECULAR CANCER RESEARCH, published by the American Association for Cancer Research, stands as a pivotal journal in the fields of cancer research, molecular biology, and oncology. With an impressive impact factor and recognized as a Q1 journal in its respective categories for 2023, it serves as an essential resource for researchers, professionals, and students aimed at advancing our understanding of cancer mechanisms and therapies. The journal, identified by the ISSN 1541-7786 and E-ISSN 1557-3125, provides a platform for cutting-edge research and clinical applications, emphasizing innovation and collaboration within the scientific community. With its focus on high-quality, peer-reviewed articles, MOLECULAR CANCER RESEARCH is vital for anyone looking to stay abreast of significant advancements in cancer biology and treatment strategies. For more details and to access the journal's content, please visit the publisher's link.

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

Journal of Cancer is a premier, peer-reviewed academic journal published by IVYSPRING INTERNATIONAL PUBLISHING that focuses on advancing the field of oncology. With an impact factor reflecting its significant contributions, this journal ranks in the 80th percentile of medical journals pertaining to oncology, positioning it at #79 out of 404 in Scopus. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that groundbreaking research reaches a global audience without barriers. Based in Australia, the journal addresses a wide array of topics within cancer research, catering to researchers, healthcare professionals, and students committed to enhancing their understanding of the complexities of cancer. Amidst evolving challenges in oncology, the Journal of Cancer serves as a vital platform for disseminating innovative findings, fostering collaboration, and promoting informed decisions that can lead to improved cancer outcomes worldwide.

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.